Storia in 4 fonti

At BIO, tension over China biotech deal regulation looms

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mese fa

At BIO, tension over China biotech deal regulation looms

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.

originale

Timeline cronologica

martedì 23 giugno 2026·endpoints.news
BIO board spoke with national security, health officials on China, CEO says
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall under COINS Act.
giovedì 25 giugno 2026·statnews.com
Biosecure didn’t stop China’s rise in biotech. Some lawmakers want to do more
They're laying the groundwork for legislation and regulation to counter Chinese biopharma companies.

At BIO, tension over China biotech deal regulation looms

Confronto fonti

At BIO, tension over China biotech deal regulation looms

Timeline cronologica

BIO board spoke with national security, health officials on China, CEO says

Biosecure didn’t stop China’s rise in biotech. Some lawmakers want to do more

In Depth: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad

BIO board spoke with national security, health officials on China, CEO says

Biosecure didn’t stop China’s rise in biotech. Some lawmakers want to do more

At BIO, tension over China biotech deal regulation looms

In Depth: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad